Equities analysts expect Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to post $0.63 earnings per share for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Teva Pharmaceutical Industries’ earnings, with the highest EPS estimate coming in at $0.67 and the lowest estimate coming in at $0.57. Teva Pharmaceutical Industries reported earnings of $0.53 per share during the same quarter last year, which suggests a positive year over year growth rate of 18.9%. The business is expected to report its next quarterly earnings report on Wednesday, February 12th.

On average, analysts expect that Teva Pharmaceutical Industries will report full-year earnings of $2.39 per share for the current year, with EPS estimates ranging from $2.25 to $2.45. For the next fiscal year, analysts forecast that the firm will post earnings of $2.51 per share, with EPS estimates ranging from $2.13 to $2.74. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.56 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). The business had revenue of $4.26 billion during the quarter, compared to the consensus estimate of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%.

A number of brokerages have issued reports on TEVA. Wells Fargo & Co reduced their price objective on Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating for the company in a research note on Monday, September 30th. Gabelli upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday, October 16th. ValuEngine downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 3rd. Bank of America upgraded Teva Pharmaceutical Industries from an “underperform” rating to a “buy” rating in a research note on Friday, January 3rd. Finally, JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $8.00 price objective for the company in a research note on Tuesday, November 12th. Four equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $10.64.

In related news, VP Hafrun Fridriksdottir sold 4,310 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.49, for a total transaction of $45,211.90. Following the sale, the vice president now owns 24,883 shares of the company’s stock, valued at approximately $261,022.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.49% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Pacer Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $32,000. AdvisorNet Financial Inc raised its holdings in shares of Teva Pharmaceutical Industries by 71.3% in the 3rd quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock valued at $25,000 after acquiring an additional 1,525 shares in the last quarter. Motco purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $28,000. Lindbrook Capital LLC raised its holdings in shares of Teva Pharmaceutical Industries by 76.6% in the 3rd quarter. Lindbrook Capital LLC now owns 4,461 shares of the company’s stock valued at $31,000 after acquiring an additional 1,935 shares in the last quarter. Finally, G&S Capital LLC raised its holdings in shares of Teva Pharmaceutical Industries by 49.9% in the 3rd quarter. G&S Capital LLC now owns 6,012 shares of the company’s stock valued at $41,000 after acquiring an additional 2,000 shares in the last quarter. 53.38% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE:TEVA opened at $10.04 on Friday. The company has a market capitalization of $10.32 billion, a PE ratio of 3.59, a price-to-earnings-growth ratio of 0.90 and a beta of 1.81. The company has a debt-to-equity ratio of 1.62, a current ratio of 0.89 and a quick ratio of 0.56. The business has a fifty day moving average price of $9.76 and a two-hundred day moving average price of $8.40. Teva Pharmaceutical Industries has a 1 year low of $6.07 and a 1 year high of $20.21.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: Trading Stocks – What are percentage gainers?

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.